BioForce Nanosciences Holdings, Inc. reported no revenue for the fiscal years ending December 31, 2025, and December 31, 2024, as the company continues to struggle with sales of its "BioForce Eclipse" nutritional supplement product. The company recorded a net loss of $1,291,951 for 2025, a significant increase from the previous year's loss of $490,437. This increase in loss was attributed to a liability settlement of $801,193. General and administrative expenses slightly decreased to $66,951 in 2025 from $67,437 in 2024, reflecting a reduction in professional service fees.
The company has undergone significant changes in its business model, shifting from manufacturing nano-particular measurement devices to focusing on nutritional supplements since 2015. New management has been appointed, including Co-CEOs Steve Gagnon and John LaViolette, and President Sasha Shapiro, as part of a strategic effort to revitalize the company. BioForce is actively pursuing a marketing campaign to enhance brand awareness and expand its customer base, targeting retailers, gyms, and online platforms for its products.
Despite these efforts, BioForce reported no customer sales during the 2022 and 2023 fiscal years, indicating a need for a more effective marketing strategy. The company plans to broaden its customer outreach through direct marketing and B2B sales campaigns, with a focus on health-conscious individuals and various retail channels. The company aims to increase its market share in the $36 billion vitamin and supplement industry, which is projected to grow at an average rate of 2.5% annually.
As of December 31, 2025, BioForce's total assets were reported at $786, while total liabilities stood at $619,329, leading to an accumulated deficit of $162,411,310. The company has expressed substantial doubt about its ability to continue as a going concern without raising additional capital. Management has indicated that it will seek funding through debt or equity financing to support ongoing operations and implement its business plan.
Looking ahead, BioForce intends to evaluate new product lines and marketing strategies to attract environmentally conscious consumers, including the introduction of biodegradable packaging. The company remains focused on expanding its presence in the nutritional supplement market, although it acknowledges the competitive landscape and the challenges it faces in achieving profitability.
About BIOFORCE NANOSCIENCES HOLDINGS, INC.
BioForce Nanosciences Holdings, Inc. operates in the nutritional supplements industry, focusing on natural vitamins, minerals, powders, and beverages designed to support healthier lifestyles for active individuals across all ages. Its core product, BioForce Eclipse, is a private-label multivitamin and mineral powder marketed through distributors, retailers, and online channels. The company leverages contract manufacturing and private labeling to deliver quality supplements targeting athletes, health-conscious consumers, and the elderly in the U.S. market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.